-
Sino Biological and BioGeometry Broaden Partnership to Advance AI-Driven Drug Discovery
•
Sino Biological (SHE: 301047), a leading biotech company in China, and BioGeometry have announced an expansion of their partnership to harness generative artificial intelligence (AI) for drug discovery. While the financial details of the deal remain undisclosed, the collaboration aims to combine Sino Bio’s advanced protein expression and wet-lab expertise…
-
BioGeometry and Sanyou Biopharmaceuticals Forge AI Partnership for Antibody Drug Discovery
•
BioGeometry, an AI-driven pharmaceutical company based in Beijing, has formed a strategic partnership with Sanyou Biopharmaceuticals Co., Ltd. The collaboration aims to harness their combined expertise in generative AI technology for target discovery, with the goal of developing IND-stage drugs and creating an advanced AIGC-driven antibody drug discovery platform. The…
